Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013.
about
Global Emergence and Dissemination of Enterococci as Nosocomial Pathogens: Attack of the Clones?Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance TrialGlobal Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial.Tigecycline Nonsusceptibility Occurs Exclusively in Fluoroquinolone-Resistant Escherichia coli Clinical Isolates, Including the Major Multidrug-Resistant Lineages O25b:H4-ST131-H30R and O1-ST648.Fluorocycline TP-271 Is Potent against Complicated Community-Acquired Bacterial Pneumonia Pathogens.Prescription Patterns for Tigecycline in Severely Ill Patients for Non-FDA Approved Indications in a Developing Country: A Compromised OutcomeTetracycline Antibiotics and Resistance.In vitro selection of Staphylococcus aureus mutants resistant to tigecycline with intermediate susceptibility to vancomycin.Intravenous Minocycline: A Review in Acinetobacter Infections.Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia.Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects.Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens
P2860
Q26745991-56B3C0D6-A89C-4EA4-A5A5-16CC2D6A3B8FQ33901518-2D29A852-5204-4B0F-92B4-E066914CE41EQ37593067-DBF3E3B4-E5F9-48F8-88C4-E3134368E194Q37612974-D01BB4F4-DCA4-4B14-960C-AB21D3E7F9ABQ37661000-6CBEB810-0CD2-46D8-98B5-8B59970C03E4Q37721240-469A2948-A8A9-473B-889E-A9645276D19CQ38779243-40E48AA1-EDB1-4467-8CD9-9518BAFE8F98Q38840019-FB7836DB-E17C-49AD-8EFD-851CD4A594E3Q38940459-E83206AE-70EA-4067-B62A-023DF5BEF814Q47761002-B99B4B30-38DE-47AB-9FDA-9998EFD836B2Q50134161-6088CBEF-049B-4189-A950-A9E7625B7475Q58703866-E78585BE-70B9-41C6-B69D-64A624D36A5D
P2860
Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Global in vitro activity of ti ...... Surveillance Trial 2004-2013.
@ast
Global in vitro activity of ti ...... Surveillance Trial 2004-2013.
@en
type
label
Global in vitro activity of ti ...... Surveillance Trial 2004-2013.
@ast
Global in vitro activity of ti ...... Surveillance Trial 2004-2013.
@en
prefLabel
Global in vitro activity of ti ...... Surveillance Trial 2004-2013.
@ast
Global in vitro activity of ti ...... Surveillance Trial 2004-2013.
@en
P2093
P2860
P1476
Global in vitro activity of ti ...... Surveillance Trial 2004-2013.
@en
P2093
Daryl J Hoban
Michael J Dowzicky
Ralf Rene Reinert
Samuel K Bouchillon
P2860
P2888
P356
10.1186/S12941-015-0085-1
P577
2015-05-10T00:00:00Z
P5875
P6179
1013280940